ClinicalTrials.gg
Not yet recruitingNCT07945132Updated Nov 18, 2026

An Observational Study of the Medical-Grade Wireless Wearable Data for Predicting Hypoxemia Risk and Evaluating Workflow Efficiency in Patients Undergoing Sedated Gastrointestinal Endoscopy

An observational study in Hypoxemia, sponsored by Min Su. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Min Su · Observational

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
772
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.

Planned enrollment
5th of 19
772 · median 120
Started
2026
with 18 others
Observational
19 of 97
5 open now
Primary completion
2028-04
later than 41 of 44 live
Registered
97th of 97
by date

Among the 97 studies in Hypoxia with a site in China, this one is the 5th largest by planned enrollment of the 19 observational ones that give a count, is one of 19 that started in 2026, is one of 19 observational ones, reaches primary completion later than 41 of the 44 other live ones, and was the 97th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

This prospective observational study aims to develop and evaluate prediction models for low blood oxygen levels (hypoxemia) in adult patients undergoing gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia. The study will also assess patient flow and waiting times during different stages of endoscopy care.

Low blood oxygen levels may occur during anesthesia and recovery from endoscopy. Medical-grade wireless wearable monitoring devices can continuously record vital signs as patients move through preparation, examination, transfer, and recovery areas. The investigators will analyze monitoring data, routine clinical information, and the time spent at different stages of care to identify factors associated with hypoxemia and potentially avoidable nonmedical waiting time.

This study will be conducted at the First Affiliated Hospital of Chongqing Medical University. Approximately 772 adult participants are planned for enrollment in the current study phase. All participants will receive routine anesthesia, endoscopy, monitoring, and recovery care. The study will not change clinical treatment decisions, and prediction model results will not be used to guide patient care.

The findings may support future improvements in patient safety monitoring, hypoxemia risk assessment, and endoscopy workflow efficiency. Participants may not receive any direct medical benefit from taking part in this study.

Read the detailed description

Background and Rationale Hypoxemia is an important safety concern during gastrointestinal endoscopy under anesthesia. Changes in oxygen saturation may occur during both the procedure and the recovery period. Continuous monitoring using medical-grade wireless wearable devices may provide useful physiological data for predicting hypoxemia. In addition, the time required for different stages of endoscopy care may be influenced by patient characteristics, clinical needs, and operational factors. Distinguishing medically necessary care from avoidable nonmedical waiting may help improve workflow efficiency without compromising patient safety.

Study Design and Data Collection This investigator-initiated, prospective observational cohort study will be conducted at the First Affiliated Hospital of Chongqing Medical University. The current phase involves single-center model development and internal validation.

Adult patients scheduled for gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia will be assessed for eligibility and enrolled after written informed consent.

Medical-grade wireless wearable monitoring devices already used in routine clinical care will provide continuous physiological data, including peripheral oxygen saturation (SpO2), heart rate, and signal quality information. Additional study data will include routine pre-anesthesia assessments, patient characteristics, anesthesia and endoscopy records, airway management, recovery information, and workflow timestamps. Simple noninvasive measurements, including neck circumference and thyromental distance, will also be collected.

Hypoxemia Prediction Two prediction objectives will be evaluated. Model A will use information available before the first administration of anesthetic medication to predict hypoxemia occurring between the first anesthetic dose and endoscope removal.

Model B will evaluate the risk of hypoxemia during recovery, from completion of handover to the recovery area until the patient first meets discharge criteria. Development of Model B will depend on the availability of sufficient outcome events and data.

Hypoxemia will be defined as an SpO2 below 90%, after excluding measurement artifacts. Prediction models will be developed and internally validated using prespecified statistical and machine-learning methods. Additional temporal and external validation may be conducted in subsequent study phases after the required approvals.

Workflow Efficiency Assessment Standardized timestamps will be collected across patient check-in, preparation, monitoring, examination, transfer, recovery, discharge, and room turnover. Risk-adjusted analyses will assess variations in the duration of different workflow stages.

The main workflow efficiency outcome will be the cumulative duration of system-attributable nonmedical waiting time, confirmed by structured documentation of operational causes. Time required for necessary medical treatment, monitoring, and recovery will not be classified as avoidable waiting.

Patient Safety and Study Procedures This study is observational and will not alter routine anesthesia, endoscopy, monitoring, treatment, recovery, or discharge decisions. Prediction model results will not be disclosed to the clinical team for decision-making during the current study phase.

Research data will be de-identified and handled using appropriate data protection procedures. Available hospital records may be reviewed within 24 hours after discharge from the endoscopy center to identify relevant safety events. No additional invasive procedures or study-directed treatments will be performed.

03

Conditions studied

  • Hypoxemia

Browse trials for

Keywords

  • Gastrointestinal Endoscopy
  • Wireless Wearable Monitoring
  • Predictive Models
  • Workflow Efficiency
  • Anesthesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients aged 18 years or older who are scheduled to undergo gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia at the First Affiliated Hospital of Chongqing Medical University, China. Potential participants will be identified through routine pre-anesthesia assessment and outpatient clinical services. Eligible patients with an ASA-PS classification of I-III who receive routine medical-grade wireless wearable monitoring will be invited to participate after screening. Written informed consent will be obtained before enrollment. Approximately 772 participants are planned for the current single-center observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Scheduled to undergo gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia, with routine medical-grade wireless wearable monitoring.
  • Physical Status (ASA-PS) classification I-III before anesthesia.
  • Able to understand the study information, voluntarily agree to participate, and provide written .

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • Emergency endoscopy.
  • Preprocedural hypoxemia requiring advanced respiratory support.
  • Uncontrolled severe cardiopulmonary disease before the procedure.
  • Requirement for general anesthesia with endotracheal intubation, intensive care unit (ICU)-level support, or planned transfer to the ICU after the procedure.
  • Active major bleeding, a clearly full stomach, an anticipated difficult airway requiring a special anesthetic strategy, or other extremely high-risk conditions unsuitable for routine anesthesia management in an endoscopy center.
  • Missing critical outcome information that prevents determination of the primary safety outcome.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
772 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients Undergoing Gastrointestinal Endoscopy Under Anesthesia

    This cohort consists of adult patients aged 18 years or older who are scheduled to undergo gastroscopy, colonoscopy, or combined gastrointestinal endoscopy under anesthesia at the First Affiliated Hospital of Chongqing Medical University. Eligible patients have an American Society of Anesthesiologists Physical Status (ASA-PS) classification of I-III and provide written informed consent. All participants receive routine anesthesia, endoscopic examination, and medical-grade wireless wearable monitoring according to standard clinical practice. Physiological monitoring data, clinical information, and workflow timestamps will be collected prospectively for hypoxemia prediction model development and workflow efficiency assessment. No additional study-directed clinical intervention will be performed.

06

What researchers measure

Primary outcomes

  1. Incidence of Hypoxemia During Gastrointestinal Endoscopy

    The proportion of participants experiencing at least one episode of hypoxemia between the first administration of anesthetic medication (T6) and endoscope removal (T8). Hypoxemia is defined as peripheral oxygen saturation (SpO2) below 90% at any time, after exclusion of measurement artifacts caused by movement, poor perfusion, or sensor displacement. Events will be adjudicated using monitoring data and clinical records.

    Time frame: From the first administration of anesthetic medication until endoscope removal, during the endoscopy procedure.

  2. Cumulative System-Attributable Nonmedical Waiting Time

    The cumulative duration, in minutes, of system-attributable nonmedical waiting time per participant. Waiting episodes must have a documented operational cause, traceable start and end times, and no ongoing medical need for treatment, observation, or technical management. Operational causes include delays related to equipment, procedure rooms, staffing, recovery beds, transportation, handover, documentation, patient education, accompanying persons, cleaning, or supply preparation. Medically necessary care and recovery time will be excluded.

    Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure.

Secondary outcomes

  1. Incidence of Hypoxemia During Postanesthesia Recovery

    The proportion of eligible participants experiencing hypoxemia (SpO2 below 90%, after artifact exclusion) after completion of handover to the recovery area (T10) and before first meeting discharge criteria (T12). The analysis will include participants without the recovery-period target event at T10 who have the required landmark variables. Formal model development is conditional on sufficient outcome events.

    Time frame: From completion of handover to the postanesthesia recovery area until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  2. Incidence of Severe Hypoxemia

    The proportion of participants experiencing severe hypoxemia, defined as SpO2 below 75%, or SpO2 between 75% and 90% lasting at least 60 seconds, according to the study protocol.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  3. Ratio of Hypoxemia Area Under the Curve to Duration

    The area under the SpO2 curve for measurements below 90% divided by the cumulative duration of SpO2 below 90%, according to the prespecified analysis methodology.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  4. Incidence of Clinically Recognized Respiratory Events

    The number and proportion of participants with clinically recognized apnea, airway obstruction, laryngospasm, bronchospasm, regurgitation, or aspiration. Event types will be reported separately.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  5. Incidence of Airway Interventions

    The number and proportion of participants requiring positional adjustment, jaw thrust, increased oxygen flow, oropharyngeal or nasopharyngeal airway placement, positive-pressure mask ventilation, or unplanned tracheal intubation. Intervention types will be reported separately.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  6. Incidence of Hypotension

    The proportion of participants with systolic blood pressure below 90 mmHg or a decrease greater than 30% from baseline. Treatment for hypotension will also be documented.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  7. Incidence of Bradycardia

    The proportion of participants with heart rate below 50 beats per minute. Treatment for bradycardia will also be documented.

    Time frame: From the first administration of anesthetic medication until the participant first meets discharge criteria, on the day of the endoscopy procedure.

  8. Occurrence of Major Clinical Complications

    The number and type of major clinical complications, including severe gastrointestinal bleeding, gastrointestinal perforation, unplanned emergency department transfer, intensive care unit admission or hospitalization, cardiac arrest, and death. Individual event categories will be reported separately.

    Time frame: From check-in at the endoscopy center through 24 hours after actual departure from the endoscopy center.

  9. Total Endoscopy Center Length of Stay

    Total time in minutes from endoscopy center check-in (T1) to actual departure from the endoscopy center (T13).

    Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure.

  10. Duration of Individual Endoscopy Workflow Stages

    Duration in minutes of each adjacent workflow stage from T1 through T13, including preparation, examination, transfer, recovery, and discharge-related stages. Stage-specific values will be reported.

    Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure; each consecutive workflow stage will be assessed separately.

  11. Procedure Room Turnover Time

    Time in minutes from a participant leaving the procedure area (T9) until the next patient enters the same procedure room (T14). Prespecified exceptions will be excluded or reported separately.

    Time frame: From departure of the participant from the procedure area until the next patient enters the same procedure room, on the day of the endoscopy procedure.

  12. Risk-Adjusted Excess Workflow Duration

    The difference between observed and expected workflow duration estimated using prespecified risk-adjusted stage-specific time models. Results will be evaluated by workflow stage.

    Time frame: From check-in at the endoscopy center until actual departure from the endoscopy center, on the day of the endoscopy procedure; each workflow stage will be evaluated separately.

07

Study locations

1 site
08

References and documents

Publications

  • Zhu B, Huang Y, Liu Y, Wang M, Liu L. Application of the wireless wearable monitoring system improves the turnaround time in gastrointestinal endoscopy center. Postgrad Med J. 2025 Aug 17;101(1199):873-879. doi: 10.1093/postmj/qgaf103. PubMed 40583580 ↗
  • Fang Z, Zou D, Xiong W, Bao H, Zhao X, Chen C, Si Y, Zou J. Dynamic prediction of hypoxemia risk at different time points based on preoperative and intraoperative features: machine learning applications in outpatients undergoing esophagogastroduodenoscopy. Ann Med. 2023 Dec;55(1):1156-1167. doi: 10.1080/07853890.2023.2187878. PubMed 37140918 ↗

Individual participant data

Plan to share: No — De-identified individual participant data (IPD) may be made available upon reasonable request to the corresponding author following publication of the primary study findings. Data sharing will be subject to approval by the relevant institutional ethics committee and execution of a data use agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 16 months is below that.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945132
Lead sponsor
Min Su
Responsible party
Min Su (professor, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Yang Hu
Contact
987273396@qq.com
+86 18371751707
Su Min
principal investigator · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion